Clinical Study

Iov-Com-202- A Phase 2, Multicenter Study Of Autologous Tumor Infiltrating Lymphocytes (Ln 144/Ln-145/Ln-145-S1) In Patients With Solid Tumors

Posted Date: Nov 28, 2020

  • Investigator: Trisha Wise-Draper
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

This is a prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL LN-144 (Lifileucel)/LN-145 in combination with pembrolizumab or TIL LN-145/LN-145-S1 as a single therapy. The primary outcome measured for this study is Objective response rate.


To Be Eligible: Must Have Confirmed Diagnosis Of Malignancy Of Their Receptive Histologies: Unresectable Or Metastatic Melanoma Stage Iiic/Iv, Advanced Recurrent Or Metastatic Hnscc, Or Stage Iii/Iv Nsclc, Ecog 0-1, Life Expectancy >6 Months, No Active Illnesses That Increase Study Participant Risk, No Prior Malignancy Within 3 Years, No Hypersensitivity To Study Drugs Or Components


Advanced Solid Tumors

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.